Campbell's Mourns the Death of Long-time Board Member Mary Alice Dorrance Malone
BUSINESS WIRE)-- The Campbell's Company (NASDAQ:CPB) and the company's Board of Directors mourn Mary Alice Dorrance Malone who recently passed away at the age of 75. Malone was the longest-tenured member of Campbell's Board of Directors with 35 years of service.
Malone was the granddaughter of Dr. John T. Dorrance, the inventor of condensed soup and President of the company from 1914-1930, and the daughter of John T. Dorrance Jr., a former Chair of the company from 1962-1984. She was elected to the Board in 1990 and served with distinction on many of the board's standing committees, most recently on the Governance and Compensation & Organization committees.
Keith R. McLoughlin, Chair of the Board, said, 'We are deeply saddened by the passing of Mary Alice. As a descendent of the company's founder and a significant long-term shareholder, her contributions to grow and protect Campbell's legacy were immeasurable. She will be missed in our board meetings and as a friend and colleague. On behalf of my fellow board members, we extend our heartfelt condolences to her family and friends.'
Malone was an entrepreneur, a private investor, and a philanthropist, having served for many years on the boards of several nonprofit organizations and actively participated in many philanthropic endeavors. Her passion and primary business were equestrian sports. She was President of Iron Spring Farm horse breeding and performance centers in Pennsylvania and Florida, which she founded in 1976.
Mick Beekhuizen, Campbell's President and Chief Executive Officer, said, 'Mary Alice was a highly committed director and helped guide the company through many chapters. Her extensive knowledge of Campbell's history, organization and culture, and her love for our food and iconic brands were invaluable to management and the board. Her positive impact on the company will last for generations to come. Everyone at Campbell's offers our deepest condolences to her loved ones.'
Malone is survived by two daughters.
Funeral arrangements are not public. The family respectfully requests privacy during this time of mourning.
The board will be considering the election of a new member.
About The Campbell's Company
For 155 years, The Campbell's Company (NASDAQ:CPB) has been connecting people through food they love. Headquartered in Camden, N.J. since 1869, generations of consumers have trusted Campbell's to provide delicious and affordable food and beverages. Today, the company is a North American focused brand powerhouse, generating fiscal 2024 net sales of $9.6 billion across two divisions: Meals & Beverages and Snacks. The Campbell's portfolio of 16 leadership brands includes: Campbell's, Cape Cod, Chunky, Goldfish, Kettle Brand, Lance, Late July, Pace, Pacific Foods, Pepperidge Farm, Prego, Rao's, Snack Factory pretzel crisps, Snyder's of Hanover, Swanson and V8. For more information, visit www.thecampbellscompany.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
VanEck Outlines Ways To Tackle Emerging Risk To Bitcoin Treasury Companies
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. VanEck Head of Digital Assets Research Matthew Sigel has joined the wave of experts warning that the Bitcoin treasury model popularized by MicroStrategy (NASDAQ:MSTR) faces risks. Sigel said Monday on X that Bitcoin treasury firms risked eroding shareholder value if they traded near their net asset value. Multiples to NAV have allowed Bitcoin treasury firms to raise capital for Bitcoin purchases by issuing more shares. But in recent weeks, experts have warned that these premiums will likely erode over time as the asset becomes more accessible and normalized and more treasury firms appear. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . 'If the stock trades at or near NAV, continued equity issuance can dilute rather than create value,' Sigel said. 'That is not capital formation. It is erosion.' However, there may still be room for Bitcoin treasury firms to safeguard against this risk, according to Sigel. Sigel said Bitcoin treasury firms should announce a pause of at-the-market stock offerings if shares trade below 0.95 times NAV for 10 days or more. This could temporarily prevent further shareholder dilution. Sigel also said that firms could engage in stock buybacks when Bitcoin rises, but share prices fail to reflect the increased value. This strategy is typically employed when a firm believes its stock is undervalued, and it can often be an effective means of returning shareholder value. Still, its effectiveness is often at the mercy of broader market sentiment. If all fails, Sigel said, firms might have to consider more drastic measures such as mergers, spinoffs, or sunsetting the Bitcoin treasury strategy. Trending: New to crypto? on Coinbase. Meanwhile, he warned that Bitcoin treasury firms should avoid outsized executive compensation. He said compensation should reflect NAV per share growth, not the total Bitcoin position or share count. 'Boards and shareholders should act with discipline now, while they still have the benefit of optionality,' he surmised. Sigel's warning comes as this NAV risk looks set to become a reality for at least one Bitcoin treasury firm. At last look, Semler Scientific (NASDAQ:SMLR) is trading at 1 times NAV, according to Strategy Tracker. The firm's stock has fallen over 45% year-to-date despite multiple Bitcoin purchases over the year and the asset trading near all-time highs. According to Sigel, Semler Scientific's troubles may be linked to its small market capitalization, low liquidity and long-standing business issues. The firm has been at the center of a multiyear Department of Justice probe over whether it misled government programs with false claims about its QuantaFlo test to get more money than it should have from the government. The QuantaFlo test uses Semler Scientific's QuantaFlo device to test for peripheral artery disease. QuantaFlo has been used by large insurance firms like United Healthcare. Failure of Semler Scientific to rally could offer insight into what other Bitcoin treasury firms could face and how it could impact the market. Read Next: A must-have for all crypto enthusiasts: . Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Image: Shutterstock This article VanEck Outlines Ways To Tackle Emerging Risk To Bitcoin Treasury Companies originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering. Housing market weakness triggers Lennar to offer biggest incentives since 2009 The Trump administration is trying to bring back asbestos How one company is revolutionizing the way we use everyday water The diagnostics company's IPO follows the successful debut of fintech companies like Chime Financial and Circle Internet Group, and will test whether investors are ready to embrace biotech companies despite declines in the sector for the last six months. Here's what to know about the listing. Founded in 2008 by David Dean Halbert, the healthcare company utilizes next-generation artificial intelligence (AI) and machine learning for precision medicine. Through molecular analysis, Caris specializes in cancer diagnosis and treatment. According to a recent filing to the Securities and Exchange Commission (SEC), the Irving, Texas-based company currently has over 1,700 employees and over 100 biopharmaceutical partners. The company incurred net losses of $281.9 million and $341.4 million in 2024 and 2023, respectively, on revenue of $412.3 million and $306.1 million. It is expecting additional losses in the future. Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. Caris Life Sciences will trade its stock under the ticker CAI. CAI shares were priced at $21, above their previously planned range. The IPO price was planned between the $19 and $20 range, up from the previous $16 and $18 planned price. The current pricing would value Caris Life Sciences at around $5.9 billion. CAI will trade its shared on the Nasdaq Global Select Market. Caris Life Sciences's IPO will offer 23,529,412 shares. Founder and CEO Halbert is also set to retain 41.7% of ownership following the IPO. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. It could soon have company, however, as others strive to develop their own treatments. Viking Therapeutics and Altimmune have exciting GLP-1 products entering phase 3 trials. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss. In five years, the stock has soared by close to 480%, which would have turned a $20,000 investment into approximately $116,000. The GLP-1 market is still in its early growth stages, and there's plenty of room for more companies to make names for themselves. While Eli Lilly is a safe bet to invest in right now, if you want a position in stocks that may have considerably more upside in the GLP-1 market, there are two names you should take a closer look at today: Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT). The big excitement surrounding Viking is it has a GLP-1 treatment that could be a viable option for weight loss. VK2735 isn't an approved treatment yet, but it has been showing encouraging results in early-stage trials. In data released last year, a phase 2 trial showed that the drug was able to help patients lose up to 14.7% of their body weight after 13 weeks, without signs of any plateau, suggesting further weight loss could be possible. Phase 3 trials are set to begin this year. Meanwhile, Viking is also working on an oral version of the treatment, which is currently in phase 2 trials. The phase 1 data from that looked solid, with trial participants losing up to 8.2% of their body weight after 28 days. The risk with Viking is that it isn't generating revenue today, and it doesn't have any approved products. It has incurred a net loss totaling $128 million over the trailing 12 months, and there's a real possibility that those losses could deepen as it spends more on clinical trials. If VK2735 isn't successful and doesn't obtain approval from regulators, the stock could nosedive, which is the biggest concern for investors. Investors have largely looked past Viking this year, as the healthcare stock is down 35% (as of June 13), pulling its market cap down to less than $3 billion. However, if there's encouraging clinical data to come out in the future, that could trigger a rally in Viking's stock. This is a company that has a lot of upside, and if you're OK with taking on some risk, this may be a good stock to invest in a modest amount of money into. Altimmune is similar to Viking, but it's much smaller in market capitalization, worth less than $600 million. It hasn't been as popular of an option for investors, but it's an investment that may have even greater upside, given its more modest valuation. It also has a promising GLP-1 product that investors are bullish on: pemvidutide. In a phase 2 trial, participants lost an average of 15.6% of their body weight after a period of 48 weeks on the highest dosage (2.4 mg). The company doesn't have an oral version in development, but it is also testing pemvidutide as a treatment for other conditions, including metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol liver disease. Altimmune generates limited revenue (primarily coming from grants and contracts), and until and unless it obtains approval for pemvidutide, that's likely to stay this way. Over the past four quarters, its losses have totaled $90 million, and it has burned through more than $80 million just from its day-to-day operating activities. With around $150 million in cash and short-term investments, it's adequately funded, but there is high likelihood of share offerings being necessary in the future, and dilution is a real concern for investors. If pemvidutide becomes a success, Altimmune could easily double or triple in value and potentially be an acquisition target for a larger healthcare company seeking opportunities in GLP-1. There's risk with Altimmune, but there could also be tremendous upside. If you can stomach the uncertainty, you may want to consider taking a chance on the stock. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
